Effects of Co-treatment on Endometrial abv3-integrin Expressions in Women With Recurrent Implantation Failure

Universiti Kebangsaan Malaysia Medical Centre39 enrolled

Overview

To compare the abv3-integrin expression in endometrium tissue among RIF women between the GnRH analogue with Aromatase Inhibitor (Group A) , GnRH analogue with progesterone (Group B) and GnRH analogue alone as control group (Group C)

i. To determine the abv3-integrin expression isolated from endometrium tissue from women with RIF prior to medical therapy. ii. To determine the abv3-integrin expression isolated from endometrium tissue from Group A, Group B and Group C following the medical therapy. iii. To compare the abv3-integrin expression from endometrium tissue obtained from Group A, B and C following the medical therapy. iv. To compare the implantation rates among Group A, B and C following the medical therapy. v. To compare the ongoing pregnancy among Group A, B and C following the medical therapy

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Miscarriage, Recurrent

Interventions

GNRH Analoge, Duphaston, LetrozoleDRUG

GNRH Analoge, Duphaston, Letrozole

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Women of 18 to 40 years of age * No significant pre-existing major medical. * Diagnosed as recurrent implantation failure - at least two or more failure of achieving pregnancy following embryo transfer (ET) despite the optimum endometrial thickness and good quality of embryo (unexplained). * Regular menstrual cycle atleast 3 months prior to treatment * Not taking any hormonal treatment for atlest 3months prior to recruitment * Agreed to participate Exclusion Criteria: * Concurrent significant pre-existing major medical conditions such as uncontrolled diabetes, active systemic lupus erythematosus (SLE) or Anti Phospholipid Syndrome (APS) that will interfere with implantation. * Poor quality of embryo * Suboptimal endometrial thickness(\<8mm) during the embryo transfer (ET). * On hormonal therapy prior to recruitment. * Not agreed to participate

Locations (1)

UniversitiKMMC

Kuala Lumpur, Malaysia

Outcomes

Primary Outcomes

endometrial abv3-integrin expression expressions

pre and post treatment endometrial abv3-integrin expressions

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.